Trial Profile
A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2022
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary)
- Indications Gastrointestinal stromal tumours; Paraganglioma; Phaeochromocytoma; Renal cell carcinoma
- Focus Therapeutic Use
- 27 Oct 2022 Results published in the Clinical Cancer Research
- 12 Apr 2021 Status changed from completed to discontinued.
- 31 May 2020 Results assessing the clinical activity of guadecitabine toxicities, presented at the 56th Annual Meeting of the American Society of Clinical Oncology